CALGARY, June 12, 2015 /CNW/ - Oncolytics Biotech Inc.
(TSX: ONC, NASDAQ: ONCY) today announced the voting results from
its Annual Meeting of Shareholders held on Monday June 8th, 2015. A total of
41.19% of the issued and outstanding common shares of the Company
were represented either in person or by proxy at the meeting.
In addition to the election of all nominees listed in the
management information circular dated May 6,
2015 as directors, as disclosed in the press release dated
June 9, 2015, Oncolytics shareholders
approved all other resolutions placed before the meeting (all
voting conducted by ballot with the exception of the resolution on
the appointment of auditors). These included: fixing the number of
directors to be elected at the meeting at 10; appointing Ernst
& Young, LLP as auditors of the corporation; amendments to the
stock option plan to increase the number of shares reserved for
issuance; and adoption of an incentive share award plan.
Please refer to the Company's management information circular
available on SEDAR at www.sedar.com for more details on the matters
covered at the annual meeting. Final voting results on all
matters voted on at the annual meeting will also be filed on
SEDAR.
About Oncolytics Biotech Inc.
Oncolytics is a
Calgary-based biotechnology
company focused on the development of oncolytic viruses as
potential cancer therapeutics. Oncolytics' clinical program
includes a variety of human trials including a Phase III trial in
head and neck cancers using REOLYSIN®, its proprietary
formulation of the human reovirus. For further information about
Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements, including the
Company's belief as to the potential of REOLYSIN as a cancer
therapeutic; the Company's expectations as to the success of its
research and development programs in 2015 and beyond, the Company's
planned operations, the value of the additional patents and
intellectual property; the Company's expectations related to the
applications of the patented technology; the Company's expectations
as to adequacy of its existing capital resources; the design,
timing, success of planned clinical trial programs; and other
statements related to anticipated developments in the Company's
business and technologies involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN as a cancer
treatment, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should
consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to
update these forward-looking statements, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.